Skip to content
Open access

A-40: Associations of Alzheimer’s Plasma Biomarkers with Kidney Disease Functioning

Oct 2026 · Archives of Clinical Neuropsychology · 0 citations

Abstract

Objective: Plasma concentrations of amyloid-beta 42/40 (Aβ42/40) and phosphorylated tau 217 (p-tau217) are now routinely ordered clinically in older adults as proxy markers for brain Aβ pathology in Alzheimer’s disease. Marked kidney impairment in chronic kidney disease (CKD) influences Aβ42/40 and p-tau217 measurements; however, the relationship between these plasma biomarker titers and subclinical, age-related kidney function across the estimated glomerular filtration rate (eGFR) dynamic range remains less clear. We tested in older adults the relationship between lower eGFR and higher p-tau217, as well as lower Aβ42/40. Method/Data Selection: Plasma Aβ42/40 and p-tau217 levels were measured using the LumiPulse immunoassay in 33 cognitively-intact older adults, aged 63-81 years. eGFR was quantified with a blood laboratory test. Protein values were log-transformed, and linear regression analyses examined the association between each biomarker and eGFR. Covariates (age, sex, education) were entered, with an alpha level of 0.05. Results/Data Synthesis: eGFR values ranged from 45-109 (mean=80.85, SD=14.10), while Aβ42/40 levels were between .014-.107 (mean=.085, SD=.016) and p-tau217 levels between .030-.329 (mean=.088, SD=.070). Lower eGFR was significantly associated with higher p-tau217 (b=-.02, SE=.01, p=.003, R2=.47), but not Aβ42/40 (b=-.01, SE=.01, p=.128, R2=.14). After excluding 9% of participants with eGFR< 60, the association for p-tau217 remained significant (p=.010), and an inverse association emerged for Aβ42/40 (b=-.01, SE=.01, p=.021, R2=.24). Conclusions: Lower kidney function, measured by eGFR, was associated with higher p-tau217 over the eGFR dynamic range. An association was observed for Aβ42/40 after excluding participants with clinically significant low eGFR. Blood-based Alzheimer’s biomarkers will likely need to incorporate an eGFR-related adjustment with further research to better guide clinical interpretations.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.